151 related articles for article (PubMed ID: 22547552)
1. 'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24.
Werner-Lin A; Hoskins LM; Doyle MH; Greene MH
Health (London); 2012 Nov; 16(6):636-54. PubMed ID: 22547552
[TBL] [Abstract][Full Text] [Related]
2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
3. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD
Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844
[TBL] [Abstract][Full Text] [Related]
4. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
[TBL] [Abstract][Full Text] [Related]
5. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240
[TBL] [Abstract][Full Text] [Related]
6. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
7. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer.
Hallowell N; Foster C; Eeles R; Ardern-Jones A; Watson M
Soc Sci Med; 2004 Aug; 59(3):553-65. PubMed ID: 15144764
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with decisions about clinical BRCA1/2 testing.
Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
[TBL] [Abstract][Full Text] [Related]
9. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
10. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
[TBL] [Abstract][Full Text] [Related]
11. Clinical management of BRCA1 and BRCA2 mutation carriers.
Domchek SM; Weber BL
Oncogene; 2006 Sep; 25(43):5825-31. PubMed ID: 16998496
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.
Lerman C; Hughes C; Croyle RT; Main D; Durham C; Snyder C; Bonney A; Lynch JF; Narod SA; Lynch HT
Prev Med; 2000 Jul; 31(1):75-80. PubMed ID: 10896846
[TBL] [Abstract][Full Text] [Related]
13. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
Ardern-Jones A; Kenen R; Eeles R
Eur J Cancer Care (Engl); 2005 Jul; 14(3):272-81. PubMed ID: 15952973
[TBL] [Abstract][Full Text] [Related]
14. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
15. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years.
Evans DG; Lalloo F; Hopwood P; Maurice A; Baildam A; Brain A; Barr L; Howell A
Eur J Surg Oncol; 2005 Dec; 31(10):1112-8. PubMed ID: 16005602
[TBL] [Abstract][Full Text] [Related]
16. Five families living with hereditary breast and ovarian cancer risk.
Norris J; Spelic SS; Snyder C; Tinley S
Clin J Oncol Nurs; 2009 Feb; 13(1):73-80. PubMed ID: 19193551
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
18. Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.
Heisey RE; Carroll JC; Warner E; McCready DR; Goel V
Can Fam Physician; 1999 Jan; 45():114-24. PubMed ID: 10889864
[TBL] [Abstract][Full Text] [Related]
19. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]